Ring Therapeutics Inc. is a privately held, early-stage biotechnology company pioneering a completely novel form of gene therapy by exploiting a family of naturally occurring commensal viruses to create the first re-doseable and targetable DNA medicines. This approach enables a powerful new class of tropic, persistent, non-integrating vectors that overcome the immunogenicity, and limited tropism of existing gene therapy vectors. Ring Therapeutics is leveraging this versatile technology to develop a broad pipeline of novel, targeted medicines for disease with high unmet medical need.